Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells
/in International Publications, Newcastle Disease Virus /von 2011-04-06 / J. Virol. 2011 Jun;85(12):6015-23Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus
/in International Publications, Newcastle Disease Virus, NSCLC /von 2011-04-06 / Arch. Virol. 2011 Aug;156(8):1335-44Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-29IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2011-02-09 / Cancer Res. 2011 Apr;71(7):2497-506[Roles of Newcastle disease virus in human acute monocytic leukemia in vitro and in vivo]
/in Acute Leukemia, International Publications, Newcastle Disease Virus /von 2011-02-01 / Zhongguo Dang Dai Er Ke Za Zhi 2011 Feb;13(2):149-52Oncolytic virus-initiated protective immunity against prostate cancer
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2011-01-18 / Mol. Ther. 2011 Apr;19(4):797-804Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-12-18 / Vaccine 2011 Feb;29(6):1185-93Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-52Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer
/in International Publications, Newcastle Disease Virus /von 2010-11-04 / Head Neck 2011 Oct;33(10):1394-9IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de